Cox regression analysis for the overall survival in MDS patients
| Factor . | Hazard ratio . | 95% CI . | P . | |
|---|---|---|---|---|
| SRSF2 | Mutation (+) | 1.41 | 0.87∼2.30 | .166 |
| Mutation (−) | 1.0 (reference) | |||
| IPSS | INT-2/high | 2.33 | 1.40∼3.90 | .001 |
| Low/INT-1 | 1.0 (reference) | |||
| FAB subtype | CMML | 0.79 | 0.46∼1.36 | .387 |
| RA/RARS | 0.40 | 0.23∼0.72 | .002 | |
| RAEB/RAEBT | 1.0 (reference) | |||
| Age, y | > 50 | 3.36 | 1.91∼5.89 | < .001 |
| ≦ 50 | 1.0 (reference) | |||
| Factor . | Hazard ratio . | 95% CI . | P . | |
|---|---|---|---|---|
| SRSF2 | Mutation (+) | 1.41 | 0.87∼2.30 | .166 |
| Mutation (−) | 1.0 (reference) | |||
| IPSS | INT-2/high | 2.33 | 1.40∼3.90 | .001 |
| Low/INT-1 | 1.0 (reference) | |||
| FAB subtype | CMML | 0.79 | 0.46∼1.36 | .387 |
| RA/RARS | 0.40 | 0.23∼0.72 | .002 | |
| RAEB/RAEBT | 1.0 (reference) | |||
| Age, y | > 50 | 3.36 | 1.91∼5.89 | < .001 |
| ≦ 50 | 1.0 (reference) | |||